Friday, July 10, 2026

pharma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · metastatic or unresectable, recurrent HNSCC

Createrna Science and

News and analysis for Createrna Science and on NovaPharmaNews — regulatory, clinical, and market coverage.

shanghai, CN, London HQ
26 Employees
NMPA registrant Type
Company details
Status
Public
HQ
shanghai, CN, London
Employees
26
Programs
51
Drugs
87
Patents
0
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Createrna Science and — regulatory, clinical, and market coverage.

News and analysis for Createrna Science and on NovaPharmaNews — regulatory, clinical, and market coverage.

No coverage yet

We have not published news or analysis mentioning Createrna Science and yet.

Back to company overview →